

World Journal of *Clinical Oncology*

World J Clin Oncol 2024 April 24; 15(4): 464-575



EDITORIAL

- 464 Classificatory updates in verrucous and cuniculatum carcinomas: Insights from the 5th edition of WHO-IARC head and neck tumor classification
Silveira FM, Schuch LF, Bologna-Molina R
- 468 Understanding the role of transmembrane 9 superfamily member 1 in bladder cancer pathogenesis
Gade VKV, Yadav BS
- 472 Management of lateral pelvic lymph nodes in rectal cancer: Is it time to reach an Agreement?
Romero-Zoghbi SE, López-Campos F, Couñago F
- 478 Tumor infiltrating lymphocytes in gastric cancer: Unraveling complex interactions for precision medicine
Kapoor M, Sehwat A, Karthik J, Sundriyal D

REVIEW

- 482 Focus on current and emerging treatment options for glioma: A comprehensive review
Lucke-Wold B, Rangwala BS, Shafique MA, Siddiq MA, Mustafa MS, Danish F, Nasrullah RMU, Zainab N, Haseeb A
- 496 Immune pathway through endometriosis to ovarian cancer
Calmon MS, Lemos FFB, Silva Luz M, Rocha Pinheiro SL, de Oliveira Silva LG, Correa Santos GL, Rocha GR, Freire de Melo F

MINIREVIEWS

- 523 Britanin – a beacon of hope against gastrointestinal tumors?
Kajdane A, Kolat D, Zhao LY, Kciuk M, Pasieka Z, Kaluzińska-Kolat Ż
- 531 Molecular targets and mechanisms of different aberrant alternative splicing in metastatic liver cancer
Geng DY, Chen QS, Chen WX, Zhou LS, Han XS, Xie QH, Guo GH, Chen XF, Chen JS, Zhong XP

ORIGINAL ARTICLE

Retrospective Cohort Study

- 540 Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status
Niu CG, Zhang J, Rao AV, Joshi U, Okolo P

Retrospective Study

- 548 Elevated cardiovascular risk and acute events in hospitalized colon cancer survivors: A decade-apart study of two nationwide cohorts
Desai R, Mondal A, Patel V, Singh S, Chauhan S, Jain A

Basic Study

- 554** Regulation of *TMEM100* expression by epigenetic modification, effects on proliferation and invasion of esophageal squamous carcinoma

Xu YF, Dang Y, Kong WB, Wang HL, Chen X, Yao L, Zhao Y, Zhang RQ

CASE REPORT

- 566** Low-grade myofibrosarcoma of the maxillary sinus: Two case reports

Mydlak A, Ścibik Ł, Durzynska M, Zwoliński J, Buchajska K, Lenartowicz O, Kucharz J

ABOUT COVER

Peer Reviewer of *World Journal of Clinical Oncology*, Ramiro Manuel Fernández-Placencia, FACS, MD, Professor, Surgical Oncologist, Abdominal Surgery Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima Lima034, Lima, Peru. ramirofp02@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Oncology* (WJCO, *World J Clin Oncol*) is to provide scholars and readers from various fields of oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJCO mainly publishes articles reporting research results and findings obtained in the field of oncology and covering a wide range of topics including art of oncology, biology of neoplasia, breast cancer, cancer prevention and control, cancer-related complications, diagnosis in oncology, gastrointestinal cancer, genetic testing for cancer, gynecologic cancer, head and neck cancer, hematologic malignancy, lung cancer, melanoma, molecular oncology, neurooncology, palliative and supportive care, pediatric oncology, surgical oncology, translational oncology, and urologic oncology.

INDEXING/ABSTRACTING

The WJCO is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCO as 2.8; IF without journal self cites: 2.8; 5-year IF: 3.0; Journal Citation Indicator: 0.36.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Yin-Qing Zhao*; Production Department Director: *Xu Guo*; Cover Editor: *Xu Guo*.

NAME OF JOURNAL

World Journal of Clinical Oncology

ISSN

ISSN 2218-4333 (online)

LAUNCH DATE

November 10, 2010

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Hiten RH Patel, Stephen Safe, Jian-Hua Mao, Ken H Young

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2218-4333/editorialboard.htm>

PUBLICATION DATE

April 24, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Low-grade myofibrosarcoma of the maxillary sinus: Two case reports

Anna Mydlak, Łukasz Ścibik, Monika Durzynska, Jakub Zwoliński, Karolina Buchajska, Olga Lenartowicz, Jakub Kucharz

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Yoshimoto S, Japan

Received: November 16, 2023

Peer-review started: November 16, 2023

First decision: December 31, 2023

Revised: January 20, 2024

Accepted: March 20, 2024

Article in press: March 20, 2024

Published online: April 24, 2024



Anna Mydlak, Jakub Zwoliński, Karolina Buchajska, Olga Lenartowicz, Department of Head and Neck Cancer, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland

Łukasz Ścibik, Department of Otolaryngology and Head and Neck Oncological Surgery, The 5th Military Clinical Hospital with Polyclinic, Krakow 30-901, Poland

Monika Durzynska, Department of Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland

Jakub Kucharz, Department of Genitourinary Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw 02-781, Poland

Corresponding author: Monika Durzynska, PhD, Researcher, Department of Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, ul. Roentgena 5, Warsaw 02-781, Poland. niomscpi@gmail.com

Abstract

BACKGROUND

Low-grade myofibroblastic sarcoma (LGMS) is an extremely rare tumor characterized by the malignant proliferation of myofibroblasts. LGMS most commonly develops in adults, predominantly in males, in the head and neck region, oral cavity, especially on the tongue, mandible, and larynx. This article presents 2 cases of LGMS localized to the maxillary sinus and provides an overview of the available literature.

CASE SUMMARY

Two patients with LGMS located in the maxillary sinus underwent surgery at the Department of Head and Neck Surgery. Case 1: A 46-year-old patient was admitted to the clinic with suspected LGMS recurrence in the right maxillary sinus (rT4aN0M0), with symptoms of pain in the suborbital area, watering of the right eye, thick discharge from the right nostril, and augmented facial asymmetry. After open biopsy-confirmed LGMS, the patient underwent expanded maxillectomy of the right side with immediate palate reconstruction using a microvascular skin flap harvested surgically from the middle arm. The patient qualified for adjuvant radiotherapy for the postoperative bed, with an additional margin. Currently, the patient is under 1.5 years of observation with no evidence of disease. Case 2: A 45-year-old man was admitted to our clinic with facial

asymmetry, strabismus, exophthalmos, and visual impairment in the right eye. Six months earlier, the patient had undergone partial jaw resection at another hospital for fibromatosis. A contrast-enhanced computed tomography scan revealed a tumor mass in the postoperative log after an earlier procedure. An open biopsy confirmed low-grade fibrosarcoma (rT4aN0M0). The patient qualified for an extended total right maxillectomy with orbital excision and right hemimandibulectomy with immediate microvascular reconstruction using an anterolateral thigh flap. The patient subsequently underwent adjuvant radiotherapy to the postoperative area. After 9 months, recurrence occurred in the right mandibular arch below the irradiated area. The lesion infiltrated the base of the skull, which warranted the withdrawal of radiotherapy and salvage surgery. The patient qualified for palliative chemotherapy with a regimen of doxorubicin + dacarbazine + cyclophosphamide and palliative radiotherapy for bone metastases. The patient died 26 months after surgical treatment. The cases have been assessed and compared with cases in the literature.

CONCLUSION

No specific diagnostic criteria or treatment strategies have been developed for LGMS. The treatment used for LGMS is the same as that used for sinonasal cancer radical tumor excision; adjuvant radiotherapy or chemoradiotherapy should also be considered. They have low malignant potential but are highly invasive, tend to recur, and metastasize to distant sites. Patients should undergo regular follow-up examinations to detect recurrence or metastasis at an early stage. Patients should be treated and observed at the highest referral centers.

Key Words: Head and neck cancer; Paranasal sinuses; Maxillary sinus; Sarcoma; Low-grade myofibroblastic sarcoma; Case report

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Low-grade myofibroblastic sarcomas are tumors of low malignant potential; however, they are highly invasive and a high tendency to recur and metastasize to distant sites. Since only 55 cases of low-grade myofibroblastic sarcoma have been described, it is impossible to establish guidelines. As there are no specific diagnostic criteria, it is necessary to consider the occurrence of myofibroblastic sarcoma more often than reported in the literature.

Citation: Mydlak A, Ścibik Ł, Durzyska M, Zwoliński J, Buchajska K, Lenartowicz O, Kucharz J. Low-grade myofibrosarcoma of the maxillary sinus: Two case reports. *World J Clin Oncol* 2024; 15(4): 566-575

URL: <https://www.wjgnet.com/2218-4333/full/v15/i4/566.htm>

DOI: <https://dx.doi.org/10.5306/wjco.v15.i4.566>

INTRODUCTION

Low-grade myofibroblastic sarcoma (LGMS) is characterized by malignant proliferation of myofibroblasts. LGMS is extremely rare and most commonly presents on the tongue in the head and neck region. According to the literature, LGMS may also be present in the limbs, abdominal cavity, pelvis, and long bones and pelvis. Sarcomas are histologically atypical with infiltrating myoepithelial cells and morphological, immunochemical, and ultrastructural features of myofibroblast origin.

Myofibroblasts, also called modified fibroblasts, are myoepithelial cells or stellate cells of mesenchymal origin, discovered in 1971 during the healing of granulation tissue[1]. These cells have contractile properties, have characteristics of both fibroblasts and smooth muscle cells, and are present in almost every tissue[2]. In adults, myofibroblasts have also been discovered in the periodontium and around the seminiferous tubules in the testicle[3].

Myofibroblasts have an irregular, hyperchromatic, enlarged nucleus with moderate atypia in amphophilic cytoplasm [4]. They are characterized by the expression of α -Smooth muscle actin (SMA), vimentin and extra domain A of the fibronectin domain; however, they do not express smooth muscle markers Desmin and Smooth muscle myosin, differentiating them from other cells. These cells play a crucial role in physiological and pathological processes such as fibrotic diseases (lungs, kidney, intestine, and liver) and the etiopathogenesis of bronchial asthma. Myofibroblasts are particularly important during wound healing[5]. It is suspected that the transformation of fibroblasts to myofibroblasts occurs under the influence of transforming growth factor-B and extra domain A of fibronectin or the mesenchymal transformation of fibrocytes from bone marrow[1,6].

LGMS most frequently occurs in men and is extremely rare in children. It is highly malignant and characterized by metastasis to distant sites. To the best of our knowledge only 5 cases of maxillary sinus LGMS are available[2,7,8]. Patients rarely report symptoms, and the primary complaint is painless edema. Radiologically, LGMS can present a destructive growth pattern.

CASE PRESENTATION

Chief complaints

Case 1: A 46-year-old male previously treated at another hospital was admitted to the outpatient clinic of the Maria Skłodowska-Curie National Research Institute of the Oncology Department of Head and Neck Oncology. The patient presented with right-sided pain in the suborbital area, watering of the right eye, and thick discharge from the right nostril with augmented facial asymmetry.

Case 2: A 45-year-old male was admitted to Maria Skłodowska-Curie National Research Institute of Oncology presenting with strabismus, exophthalmos, and visual impairment.

History of present illness

Case 1: The patient had previously undergone surgery at another hospital for LGMS. The patient underwent resection of the maxilla using a lateral rhinotomy. A second operation was performed because of the positive surgical margins. Histopathological examination confirmed radical resection and the patient qualified for observation. Thirty months after the surgery, clinical examination confirmed an advanced tumor infiltrating the right nasal cavity, hard palate, and soft palate.

Case 2: Six months earlier, the patient underwent partial resection of the maxilla because of fibromatosis.

History of past illness

Case 1: Generally healthy, did not report chronic diseases, allergies, or medications taken regularly. At the age of 4 years, there was an electric burn on the index finger of the left hand and subsequent amputation.

Case 2: Overall healthy. He does not take medications regularly. Allergy to penicillin.

Personal and family history

Case 1: Professional driver by profession. No family history of malignancy.

Case 2: No family history of malignancy.

Imaging examinations

Case 1: Computed tomography (CT) ([Figure 1](#)) and magnetic resonance imaging (MRI) ([Figure 2](#)) of the head and neck region revealed extensive soft tissue masses in the right maxillary sinus, nasal cavity, nasopharynx, ethmoid cells, and frontal sinus. Infiltration and partial osteolysis were observed in the bone structures on the right side, including the sinus walls, hard palate, medial and suborbital bones, and pterygoid plates.

Case 2: CT, with contrast scan ([Figure 3](#)), revealed a tumor mass in the postoperative lobe after the first surgery.

Tumor infiltration was observed in the pterygopalatine and right temporal fossa. Infiltration also involved the lateral pterygoid and masseter muscle, the lateral wall of the nasal cavity and the oral cavity.

Soft tissue mass protruding from the tumor into the posterior orbit through the superior orbital fossa.

Tumor progression and rapid recurrence after primary surgery. The histopathological examination results were verified at the Maria Skłodowska-Curie National Research Institute of Oncology. After additional examinations and multispecialty consultation, the primary diagnosis was changed from fibromatosis to inflammatory myofibroblastic tumor.

Laboratory examinations

Case 1: Laboratory tests without deviations.

Case 2: Laboratory tests without any significant deviations.

Physical examination

Case 1: Facial asymmetry, highlighting of the right cheek. Eyeball movement was preserved, and the patient denied diplopia or any other deviation from the norm. On intraoral examination, an exophytic tumor of the hard palate reached the midline. Lymphadenopathy was not present during the physical examination.

Case 2: Facial asymmetry, swelling of the right cheek. Scars on the right cheek from previous surgery. Strabismus and exophthalmos of the right eye, significant visual impairment, preserved response to light.

During intraoral examination, a palpable tumor on the palate on the right side was observed. Palpable cervical bulb on the right in group 2.




Figure 1 Case 1 computed tomography scan with contrast and 3D reconstruction. Solid contrast-enhancing tumor filling the maxillary sinus and eroding the bony plate is shown. A: Sagittal section; B: Coronal section; C: Axial section; D: 3D reconstruction.




Figure 2 Case 1 T2 magnetic resonance imaging illustrating the extent of the tumor to the right maxilla sinus. A and C: Sagittal sections; B and D: Coronal sections.

FINAL DIAGNOSIS

Case 1

Histological examination confirmed the recurrence of LGMS (rpT4aN0M0) (8th Edition, American Joint Committee on Cancer) of the right maxilla, 8 cm in size. Neoplasms with spindle-cell proliferation and moderate cellular atypia.

Mitotic activity was low [four mitoses per 10 high power field (HPF)], without atypical mitosis. The collagenous stroma was partially myxoid and contained an increased number of thick-walled capillaries; no necrosis was observed. Bone destruction was also observed.

Immunohistochemistry staining performed: SMA (+, in parts of cell population), reaction type "tram truck", cytokeratin AE1 and AE3 (CKAE1/3) (-/+ , insufficient focal reaction), Mucin 4 (MUC4) (-), CD34 (-), Desmin (-), SOX10 (-), S100 protein (-), Ki-67 protein (5%), hHf35 (-), Epithelial membrane antigen (EMA) (-) (-/+), Caldesmon (-/+ , trace), H3K27me3




Figure 3 Case 2 computed tomography with contrast scan. Solid contrast-enhancing tumor filling the maxillary sinus is shown. A: Sagittal section; B: Coronal section; C: Axial section.

(+, expression prohibited), ALK (-), ROS1 (-), HMB45 (-), Melan-A (-), Myogenin (-), MyoD1 (-).

Case 2

Histopathological examination confirmed LGMS. The tumor was poorly demarcated, cream-gray in color, macroscopically without necrosis, and 8 cm in diameter with endophytic growth (rpT4aN0M0) (8th Edition, American Joint Committee on Cancer).

Microscopic examination revealed proliferation of spindle cells with moderate cellularity and focal moderate cellular atypia; mitotic activity was low (four mitoses per 10-HPF) without atypical mitosis. The collagen stroma was partially edematous without necrosis. Natural invasion was also observed.

Immunohistochemical staining performed: SMA (+), Desmin (-), CD34 (-), EMA (-), CKAE1/3 (-), Caldesmon (-), MUC1 (-), S100 protein (-), ALK1 (-), Signal transducer and activator of transcription 6 (+/-), B-creatinin (-).

TREATMENT

Case 1

Based on the physical, histopathological, and radiological examinations, the patient qualified for an expanded maxillectomy of the right side with immediate palate reconstruction using a microvascular skin flap harvested surgically from the middle arm. An intraoperative photograph was captured (Figure 4A) after buccal flap creation. The right lymph nodes were selectively resected for vascular anastomosis. Because infiltration was present within the tissues, exenteration was performed on the right side with a partial right-sided sphenoethmoidectomy (Figure 4B). Figure 5 shows the post-resection lodges. Fastened preparation of blocks. During the procedure, leakage of cerebrospinal fluid from the olfactory filament area and right sphenoid sinus was observed. Duraplasty was performed using the latae of the tensor fascia, a mucoperiosteal flap, and a topical fibrin sealant patch. The patient did not experience any complications peri- or postoperatively.

The patient qualified for adjuvant radiotherapy radiation therapy (IMRT) and cone beam CT for postoperative treatment, with additional margins. The patient received a fractional dose of 200 centigray (cGy) for a total dose of 6600 cGy.

Case 2

Open biopsy confirmed recurrence of low-grade myofibrosarcoma. Based on clinical, histopathological, and radiological results, the patient qualified for expanded complete right-sided maxillectomy and right-sided hemimandibulectomy with immediate microvessel reconstruction using an anterolateral thigh flap and selective resection of the lymph nodes on the right side. Because of infiltration of the orbital tissues, right-sided exenteration was performed.




Figure 4 Case 1 intraoperative photo and post-resection lodge. A: Intraoperative photo; B: Post-resection lodge.




Figure 5 Case 1 fastened preparation in block.

The patient qualified for adjuvant radiation therapy (IMRT) of the postsurgical bed with a fraction dosage of 200 cGy to a total dose of 6600 cGy.

OUTCOME AND FOLLOW-UP

Case 1

Currently, the patient is under observation with no evidence of disease.

Case 2

After 9 months of observation, recurrence appeared in the right mandibular arch below the irradiated area. CT confirmed the progression in both the irradiated and the previously irradiated areas. The lesion is located at the base of the skull.

There were increasing postoperative risks, which justified refrainment from radiotherapy and salvage surgery.

The patient qualified for palliative chemotherapy with doxorubicin + dacarbazine + cyclophosphamide regimen. Due to pathological L1 and L5 fractures, metastases to L1 and L2, and metastasis to the right hip bone, the patient was eligible for Radiation Therapy [fractions of 3 Gray (Gy) to a total dose of 36 Gy] and second-line chemotherapy (gemcitabine + docetaxel). The patient died 26 months after surgical treatment.

A comparison of the immunohistochemical studies of Case 1 and Case 2 is shown in [Table 1](#).

Table 1 Comparison of immunohistochemical results in Cases 1 and 2

Case	Vimentin	SMA	CK AE 1/3	Desmin	h-Caldesmon	CD 34	S100 protein	EMA	ALK 1
1	+	+	-/+	-	-/+ trace	-	-	-/+	-
2	+	+	-	-	-	-	-	-	-

+: Positive reaction; -: Negative reaction. ALK 1: Anaplastic lymphoma kinase 1; CD 34: Cluster of differentiation 34; CKAE 1/3: Cytokeratin AE1 and AE3; EMA: Epithelial membrane antigen; SMA: Smooth muscle actin.

DISCUSSION

LGMS

LGMS is a recently discovered and extremely rare malignant tumor. The first such case was diagnosed in the 1998s. In 2002, the World Health Organization made the LGMS a separate unit in the pathology and genetics of soft tissue and bone tumors[9]. Clinically, it manifests as a slow-growing and infiltrating tumor. LGMS is a low-grade malignant tumor with a high tendency for recurrence and distant metastases, even after several years[10,11].

LGMS most commonly develops in adults, predominantly in males, and in the head and neck. The tumor most often appears in the oral cavity, especially in the tongue, mandible, and larynx[6]. Other localizations include the limbs, abdominal cavity, pelvis, and long bones[12].

LGMS of the maxillary sinus is extremely rare, and only five cases have been described so far. Here, we present two more cases (Table 2)[2,7,8,13]. In cases of soft tissue sarcomas of the head and neck, MRI with contrast and/or CT with contrast should be performed (NCCN Guidelines version 2. 2022)[14]. Radiologic imaging typically shows a well-limited tumor with visible margins of destructive growth[6,10].

Histology

Histologically, the tumor is composed of spindle and stellate cells collected in clusters of different lengths, with a focal herringbone, spiral, or no pattern[13]. Cancerous cells are composed of a mild to moderate amount of pale eosinophilic cytoplasm and a spindle nucleus, which can be spiral or circular, and vesicles with cavities.

In most cases, focal atypia of the nucleus is observed; however, this is usually benign with enlarged hyperchromatic nuclei. Additionally, larger atypical cells can sometimes be observed[11].

Microscopic Figure 6A shows spindle cell infiltration, hypocellularity with mild atypia, and stromal collagen. Hypercellular proliferation and bundles of spindle cells are observed with hematoxylin and eosin staining (Figure 6B). Figure 7A shows focal expression of SMA and Figure 7B shows no expression of ALK.

Immunophenotype

Neoplastic cells in LGMS have a variable immunophenotype: Actin positive (+)/Desmin negative (-), Actin negative (-)/Desmin positive (+), and Actin positive (+)/Desmin (+) positive. In addition, tumor cells may stain positively for fibronectin. Focal expression of CD34 and Cluster of differentiation 99 has been reported, while S100 protein, epithelial markers, laminin, and h-Caldesmon are negative (-)[2,15].

Differential diagnosis

The differential diagnosis of LGMS includes both malignant and benign tumors such as nodular fasciitis, myofibroblastic tumors, fibromatosis, myofibroma, myopericytoma, monophasic synovial sarcoma, malignant peripheral nerve sheath tumors, spindle cell rhabdomyosarcoma, fibrosarcoma, leiomyosarcoma, and melanoma[5,6,16].

Procedure

The gold standard procedure in cases of sarcoma infiltrating bones is radical excision of the tumor[12,17]. In cases of positive margins, the radicalization procedure should be primarily considered. When radicalization is impossible, soft tissue margins are narrow and large. If tumors infiltrate the blood vessels or nerves, radiotherapy or chemoradiotherapy should be considered[12,18,19]. The LGMS head and neck recurrence rate is 25%-40% and is the highest when the tumor is in the nasal cavity or paranasal sinuses. A higher frequency of recurrence was observed in patients who underwent adjuvant radiation therapy. This is probably a result of the qualification of patients with unfavorable prognostic factors. The most important prognostic factor was the resection state. Positive margins, regional lymph node involvement, and age > 60 years[12].

The clinical cases presented above were characterized by characteristics specific to the described type of sarcoma, which enabled the identification of certain groups of tumors. As shown in Table 2, males are mostly affected (57%), which is also indicated in previous literature. The average age of the patients is 41 ± 17.2 years (females 45 ± 25.8 years, males 38 ± 10.6 years). The most common symptoms are nasal congestion, rhinorrhea, edema, and pain. Exophthalmos was present in two patients; however, visual impairment was present in one patient.

LGMSs are tumors of low malignancy; however, they are highly invasive, with a high tendency for recurrence and a high risk of distant metastases[6]. Several factors may contribute to this paradox of LGMS. Tumors with a low grade of malignancy may have a lower mitotic index, but this does not necessarily reflect their invasive potential or likelihood of

Table 2 Clinical features of reported cases of low-grade myofibrosarcomas of the maxillary

Ref.	Age	Sex	Size in cm	Side	Main symptoms	Necrosis	Mitotic rate, 10/10 HPF scale	Follow up in months	IHC	Results
Meng <i>et al</i> [7], 2007	33	F	6.5	Left	Nasal obstruction and leakage	Yes	10/10/HPF	12	Vimentin (+); SMA (+); Fibronectin (+); Calponin (+); Desmin (-); h-Caldesmon (-); Laminin (-); Type IV collagen (-); CD34 (-); CD68 (-); ALK1 (-)	Diagnostic testing of 1 yr
Meng <i>et al</i> [7], 2007	28	F	3	Left	Nasal obstruction and leakage	Yes	8/10 HPF	21	Vimentin (+); SMA (+); Fibronectin (+); Calponin (+); Desmin (-); h-Caldesmon (-); Laminin (-); Type IV collagen (-); CD34 (-); CD68 (-); ALK 1 (-)	Recurrent at 0.5 yr
Ghosh <i>et al</i> [2], 2019	35	M	No data	Left	Exophthalmos	No data	< 2/10 HPF	72	α -SMA (+); MIC-2 (+); Desmin (-); CD 34 (-); S100 protein (-); Cytokeratin (-); EMA (-); Calponin (-); Bcl-2 (-)	Recurrent at 6 yr
Bisceglia <i>et al</i> [13], 2001	24	M	4	Left	Pain, swelling of the midface	No data	1/10HPF	40	Vimentin (+); α -SMA (+); MSA (+); CD34 (-); Desmin (-); S100 protein (-); Cytokeratin (-)	Observation 3 yr
Gómez-Oliveira <i>et al</i> [8], 2015	75	F	No data	Left	Pain, swelling	Yes	No data	12	Vimentin (+); SMA (+); CD10 (+); Cytokeratin (+); h-Caldesmon (+); Desmin (-); CD34 (-); ALK (-); EMA (-); S100 protein (-)	After 1 yr metastasis-left femur
Current article	46	M	8	Right	Pain, swelling of the midface, nasal obstruction and leakage	No	4/10HPF	15	SMA (+) in some cells; tram truck type reaction; CK AE1/3 (-/+) focal weak reaction; MUC4 (-); CD34 (-); Desmin (-); SOX10 (-); S100 (-); Ki-67 5%; hHf35 (-); EMA (-/+) trace; Caldesmon (-/+) trace; H3K27me3 (+) preserved expression; ALK (-); ROS1 (-); HMB45 (-) Melan-A (-); Myogenin (-); MyoD1 (-)	Observation 1.5 yr
Current article	45	M	8	Right	Exophthalmos, strabismus, No visual impairment	No	4/10HPF	26	SMA (+); Desmin (-); CD34 (-); EMA (-); CKAE1/3 -; Caldesmon (-); MUC1 (-); S100 (-); ALK1 (-); STAT6 (+/-); B-catenin (-)	Recurrent

α -SMA: α -Smooth muscle actin; ALK: Anaplastic lymphoma kinase; ALK1: Anaplastic lymphoma kinase 1; Bcl-2: B-cell lymphoma 2; CD34: Cluster of differentiation 34; CD68: Cluster of differentiation 68; CKAE1/3: Cytokeratin AE1 and AE3; EMA: Epithelial membrane antigen; F: Female; H3K27me3: Trimethylation of lysine 27 on histone H3; HMB45: Human melanoma black-45; HPF: High power field; M: Male; MIC-2: Monoclonal intestinal cancer-2; MSA: Muscle specific actin; MUC1: Mucin 1; MUC4: Mucin 4; MyoD1: Myogenic differentiation 1; ROS1: Receptor tyrosine kinase 1; SMA: Smooth muscle actin; SOX10: Sex determining region Y-box 10; STAT6: Signal transducer and activator of transcription 6.

metastasis. It is suspected that these tumors may show infiltrative growth patterns, making complete surgical removal difficult, and allowing residual microscopic disease left after surgery to cause recurrence.

Even within a specific histological subtype, tumors can be significantly heterogeneous in terms of biological behavior. Some cells may have more aggressive features. Tumor behavior is also influenced by genetic and molecular characteristics. Some low-grade tumors may contain genetic changes or mutations that contribute to their ability to recur or metastasize.




Figure 6 Hematoxylin and eosin staining. A: Spindle cell infiltration, hypocellular with mild atypia, stromal collagen; hematoxylin and eosin (H&E) 20 ×; B: Hypercellular proliferation, fascicles of spindle cells; H&E 20 ×.




Figure 7 Focal expression of smooth muscle actin and no expression of anaplastic lymphoma kinase (magnification 20 ×). A: Focal expression of smooth muscle actin (magnification 20 ×); B: No expression of anaplastic lymphoma kinase (magnification 20 ×).

CONCLUSION

LGMSs are tumors of low malignant potential; however, they are highly invasive and have a high tendency to recur and metastasize to distant sites. A standard treatment strategy has not been developed yet for LGMS patients. Because of its low frequency of occurrence, it is impossible to establish guidelines. Therefore, the treatment used for LGMS is the same as that used for sino-nasal carcinoma.

It is important that LGMS patients be closely monitored by a multidisciplinary healthcare team to determine the most appropriate treatment plan and follow-up. Regular follow-up examinations are crucial to detect recurrence or metastasis at an early stage. Considering the lack of precise diagnostic criteria, LGMS occurs more often than the literature indicates and may include various clinicopathological forms.

FOOTNOTES

Author contributions: All authors made substantial contributions to the study design, data analysis and interpretation; All authors drafted the manuscript, critically revised it for important intellectual content, and read and approved the final version of the manuscript to be published.

Informed consent statement: Written informed consent was obtained from the patient to publish this paper.

Conflict-of-interest statement: The authors declare having no conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Poland

ORCID number: Anna Mydlak 0000-0003-4029-8158; Łukasz Ścibik 0000-0002-1603-9407; Monika Durzynska 0000-0003-0858-8841; Jakub Zwoliński 0000-0001-9245-5552; Karolina Buchajska 0009-0009-3376-5388; Olga Lenartowicz 0009-0001-2809-928X; Jakub Kucharz 0000-0001-5388-8910.

S-Editor: Luo ML

L-Editor: Filipodia

P-Editor: Zhao YQ

REFERENCES

- Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. *Experientia* 1971; **27**: 549-550 [PMID: 5132594 DOI: 10.1007/bf02147594]
- Ghosh A, Bandothay A, Sarkar R. Low-grade myofibroblastic sarcoma of maxillary sinus and buccal mucosa: Two rare cases and review of the literature. *Indian J Pathol Microbiol* 2019; **62**: 119-121 [PMID: 30706874 DOI: 10.4103/IJPM.IJPM_99_18]
- Eyden B. The myofibroblast: an assessment of controversial issues and a definition useful in diagnosis and research. *Ultrastruct Pathol* 2001; **25**: 39-50 [PMID: 11297318 DOI: 10.1080/019131201300004672]
- Qiu JY, Liu P, Shi C, Han B. Low-grade myofibroblastic sarcomas of the maxilla. *Oncol Lett* 2015; **9**: 619-625 [PMID: 25624890 DOI: 10.3892/ol.2014.2790]
- Fisher C. Myofibrosarcoma. *Virchows Arch* 2004; **445**: 215-223 [PMID: 15173943 DOI: 10.1007/s00428-004-1038-9]
- Demarosi F, Bay A, Moneghini L, Carrassi A. Low-grade myofibroblastic sarcoma of the oral cavity. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2009; **108**: 248-254 [PMID: 19615664 DOI: 10.1016/j.tripleo.2009.03.031]
- Meng GZ, Zhang HY, Bu H, Yang GH, Zhang XL, Yang G. Myofibroblastic sarcoma of the nasal cavity and paranasal sinus: a clinicopathologic study of 6 cases and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007; **104**: 530-539 [PMID: 17142072 DOI: 10.1016/j.tripleo.2006.08.021]
- Gómez-Oliveira G, Arribas-García I, Serrano Alvarez-Buylla A, Sánchez-Burgos R, Martínez-Pérez F, Alvarez-Flores M. Low-grade myofibroblastic sarcoma. Two rare tumours in two rare locations. *Revista Española de Cirugía Oral y Maxilofacial* 2015; **37**: 108-112 [DOI: 10.1016/j.maxilo.2013.04.004]
- Fletcher CDM, Unni KK, Mertens F. Pathology and genetics of tumours of soft tissue and bone. IARC Press; 2002. Accessed July 4, 2023. Available from: <http://www.karger.com/Article/Pdf/78490>
- Mentzel T. Myofibroblastic sarcomas: a brief review of sarcomas showing a myofibroblastic line of differentiation and discussion of the differential diagnosis. *Curr Diag Pathol* 2001; **7**: 17-24 [DOI: 10.1054/edip.2000.0057]
- Yamada T, Yoshimura T, Kitamura N, Sasabe E, Ohno S, Yamamoto T. Low-grade myofibroblastic sarcoma of the palate. *Int J Oral Sci* 2012; **4**: 170-173 [PMID: 22935748 DOI: 10.1038/ijos.2012.49]
- Xu Y, Xu G, Wang X, Mao M, Wu H, Baklaushv VP, Chekhonin VP, Peltzer K, Wang G, Zhang C. Is there a role for chemotherapy and radiation in the treatment of patients with low-grade myofibroblastic sarcoma? *Clin Transl Oncol* 2021; **23**: 344-352 [PMID: 32607812 DOI: 10.1007/s12094-020-02425-4]
- Bisceglia M, Tricarico N, Minenna P, Magro G, Pasquinelli G. Myofibrosarcoma of the upper jawbones: a clinicopathologic and ultrastructural study of two cases. *Ultrastruct Pathol* 2001; **25**: 385-397 [PMID: 11758720 DOI: 10.1080/019131201317101261]
- von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Pollack SM, Poppe M, Riedel RF, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Hang LE, Sundar H, Bergman MA. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2022; **20**: 815-833 [PMID: 35830886 DOI: 10.6004/jnccn.2022.0035]
- Mikami Y, Fujii S, Kohashi KI, Yamada Y, Moriyama M, Kawano S, Nakamura S, Oda Y, Kiyoshima T. Low-grade myofibroblastic sarcoma arising in the tip of the tongue with intravascular invasion: A case report. *Oncol Lett* 2018; **16**: 3889-3894 [PMID: 30128003 DOI: 10.3892/ol.2018.9115]
- Montgomery E, Goldblum JR, Fisher C. Myofibrosarcoma: a clinicopathologic study. *Am J Surg Pathol* 2001; **25**: 219-228 [PMID: 11176071 DOI: 10.1097/0000478-200102000-00010]
- Giraldo-Roldan D, Louredo BVR, Penafort PVM, Pontes HAR, Alves AP, Lima FCA, Fonseca TC, Abrahão AC, Romañach MJ, Fonseca FP, Delgado WA, Robinson L, Van Heerden WFP, de Almeida OP, Vargas PA. Low-Grade Myofibroblastic Sarcoma of the Oral and Maxillofacial Region: An International Clinicopathologic Study of 13 Cases and Literature Review. *Head Neck Pathol* 2023; **17**: 832-850 [PMID: 37540486 DOI: 10.1007/s12105-023-01577-3]
- Yu Y, Xiao J, Wang L, Yang G. Low-Grade Myofibroblastic Sarcoma in the Mandibular Canal: A Case Report. *J Oral Maxillofac Surg* 2016; **74**: 1505.e1-1505.e5 [PMID: 27020841 DOI: 10.1016/j.joms.2016.02.025]
- Mamukian G, Ziegler A, Block A, Thorpe E. Risk Factors for Recurrence and the Role of Radiotherapy in Low-grade Myofibroblastic Sarcoma: A Systematic Review. *Am J Clin Oncol* 2023; **46**: 420-425 [PMID: 37358303 DOI: 10.1097/COC.0000000000001025]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

